Search our Database of Scientific Publications and Authors

I’m looking for a

    5368 results match your criteria Hypophosphatemia

    1 OF 108

    Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism.
    Ann Hepatol 2017 Feb;16(2):207-214
    Department of Medicine, Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
    Background: Patients with chronic hepatitis B virus (HBV) are often treated with nucleoside/nucleotide antiviral agents and metabolic bone toxicity is a possible concern.

    Objective: To determine the relationships between fibroblast growth factor 23 (FGF23), a phosphaturic hormone, bone mineral density (BMD), and bone biochemical abnormalities in these patients.

    Material And Methods: This is a cross-sectional observational study comparing HBV-infected subjects treated for at least one year with tenofovir (TDF), lamuvidine (LVD), entacavir (ETV), or not treated (CON). Read More

    Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
    J Cancer Res Clin Oncol 2017 Feb 21. Epub 2017 Feb 21.
    Division of Hematology Oncology, Developmental Therapeutics Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
    Purpose: The ENEST1st sub-analysis presents data based on Philadelphia chromosome (Ph) status, i.e., Ph+ and Ph-/BCR-ABL1 + chronic myeloid leukemia. Read More

    Preventing Continuous Renal Replacement Therapy-Induced Hypophosphatemia: An Extended Clinical Experience with a Phosphate-Containing Solution in the Setting of Regional Citrate Anticoagulation.
    Blood Purif 2017 Feb 21;44(1):8-15. Epub 2017 Feb 21.
    Department of Nephrology and Urology, Hemodialysis Unit, Policlinico di Roma, 'Sapienza' University, Rome, Italy.
    Aims: To evaluate the efficacy and safety of a commercially available phosphate-containing solution for continuous renal replacement therapy (CRRT) in preventing CRRT-related hypophosphatemia.

    Methods: In heart surgery patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) with regional citrate anticoagulation (RCA), we combined an 18 mmol/l citrate solution with a phosphate-containing (1.2 mmol/l) dialysate/replacement fluid evaluating the incidence of hypophosphatemia and the need for parenteral phosphorus supplementation. Read More

    Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature.
    Ther Adv Endocrinol Metab 2017 Jan 21;8(1-2):14-19. Epub 2016 Nov 21.
    Department of Endocrinology and Metabolism, Concord Repatriation General Hospital, Concord, NSW, Australia.
    Iron-induced hypophosphataemic osteomalacia remains under-recognized as a potential complication of parenteral iron therapy. We here report two cases of symptomatic hypophosphataemic osteomalacia with multiple insufficiency fractures in the context of chronic gastrointestinal blood loss, necessitating monthly iron polymaltose infusions over prolonged periods of time. Respective blood tests revealed severe hypophosphataemia [0. Read More

    Treatable Leukoencephalopathy in a Patient with Hypophosphatemia.
    Case Rep Neurol 2016 Sep-Dec;8(3):264-271. Epub 2017 Jan 3.
    Department of Neurology, Kindai University Faculty of Medicine, Osakasayama, Japan.
    We report the first patient with pathologically proven leukoencephalopathy associated with hypophosphatemia. A 61-year-old woman had repetitive episodes of decreased consciousness with pontine and pallidal lesions and extensive leukoencephalopathy on MRI, later found to be associated with hypophosphatemia. Although hypophosphatemia has been linked to central pontine and extrapontine myelinolysis (osmotic myelinolysis), lesions in the deep white matter have not been reported. Read More

    Experiences with Continuous Venovenous Hemofiltration using 18mmol/L predilution Citrate anticoagulation and a Phosphate Containing Replacement Solution.
    Indian J Crit Care Med 2017 Jan;21(1):11-16
    Department of Intensive Care, Intensive Care Unit, Queen Elizabeth Hospital, Kowloon, Hong Kong.
    Context: Regional citrate anticoagulation for continuous renal replacement therapy is associated with a longer filter-life, less bleeding events and improved mortality. Problems associated with using Prismocitrate 10/2 solution in continuous renal replacement therapy, include hypomagnesemia, hypophosphatemia and the need for additional bicarbonate infusion.

    Aims: This study uses the new Prismocitrate 18/0 solution for improved buffer balance and Phoxilium solution for a more favourable electrolyte profile. Read More

    A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    BMC Musculoskelet Disord 2017 Feb 13;18(1):79. Epub 2017 Feb 13.
    Departments of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
    Background: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia, reduction of 1,25-dihydroxyl vitamin D, and bone calcification disorders. Tumors associated with TIO are typically phosphaturic mesenchymal tumors that are bone and soft tissue origin and often present as a solitary tumor. The high production of fibroblast growth factor 23 (FGF23) by the tumor is believed to be the causative factor responsible for the impaired renal tubular phosphate reabsorption, hypophosphatemia and osteomalacia. Read More

    Neurologic manifestations of major electrolyte abnormalities.
    Handb Clin Neurol 2017 ;141:705-713
    Department of Neurology, Washington University, St. Louis, MO, USA. Electronic address:
    The brain operates in an extraordinarily intricate environment which demands precise regulation of electrolytes. Tight control over their concentrations and gradients across cellular compartments is essential and when these relationships are disturbed neurologic manifestations may develop. Perturbations of sodium are the electrolyte disturbances that most often lead to neurologic manifestations. Read More

    Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
    Lancet Oncol 2017 Feb 7. Epub 2017 Feb 7.
    Klinik für Dermatologie, Venereologie und Allergologie, Universitätsklinikum Essen, Essen, Germany.
    Background: Vismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell carcinoma. Patients with multiple basal-cell carcinomas, including those with basal-cell nevus (Gorlin) syndrome, need extended treatment. We assessed the safety and activity of two long-term intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas. Read More

    Tumor-induced hypophosphatemia.
    Indian J Nephrol 2017 Jan-Feb;27(1):66-68
    Department of Nephrology, Bombay Hospital and Medical Research Center, Mumbai, Maharashtra, India.
    Significant hypophosphatemia is commonly due to Vitamin D deficiency. Any sporadic onset of hypophosphatemia in adults warrants workup to identify alternate causes. Hypophosphatemia may also be the only manifestation of an occult malignancy. Read More

    Oncogenic osteomalacia: Role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management.
    Br J Radiol 2017 Feb 9:20160811. Epub 2017 Feb 9.
    1 Department of Nuclear Medicine, SGPGIMS, Lucknow, India- 226014.
    Objectives: The aim of this study was to evaluate role of (68)Ga-DOTANOC PET/CT scan in localization of culprit lesion for biopsy and required intervention (surgical excision/radiofrequency ablation) in patients with long standing oncogenic osteomalacia (OOM)/tumor induced osteomalacia (TIO).

    Methods: 17 patients (08 male & 09 female) underwent (68)Ga-DOTANOC PET/CT scan. The patients referred with clinical and biochemical evidence of hypophosphatemia and raised Fibroblast Growth Factor-23 (FGF-23). Read More

    Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children.
    Bone 2017 Feb 4;97:287-292. Epub 2017 Feb 4.
    Yale University School of Medicine, Department of Pediatrics, New Haven, CT, United States. Electronic address:
    Objective: Hypophosphatemia occurs with inadequate dietary intake, malabsorption, increased renal excretion, or shifts between intracellular and extracellular compartments. We noticed the common finding of amino-acid based elemental formula [EF] use in an unexpected number of cases of idiopathic hypophosphatemia occurring in infants and children evaluated for skeletal disease. We aimed to fully characterize the clinical profiles in these cases. Read More

    Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients.
    Clin J Am Soc Nephrol 2017 Feb 3. Epub 2017 Feb 3.
    Department of Surgery, Asan Medical Center and University of Ulsan College of Medicine, and
    Background And Objectives: Hyperphosphatemia in kidney transplant recipients has been shown to predict poorer graft and patient survival. However, studies examining hypophosphatemia are scarce.

    Design, Setting, Participants, & Measurements: To evaluate the association of serum phosphorus level with patient and graft survival, we performed a retrospective multicenter cohort study. Read More

    Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics.
    Bone 2017 Jan 31. Epub 2017 Jan 31.
    Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address:
    Phosphate is critical for many cellular processes and structural functions, including as a key molecule for nucleic acid synthesis and energy metabolism, as well as hydroxyapatite formation in bone. Therefore it is critical to maintain tight regulation of systemic phosphate levels. Based upon its broad biological importance, disruption of normal phosphate homeostasis has detrimental effects on skeletal integrity and overall health. Read More

    Legionnaire's Disease: A Clinical Diagnostic Approach.
    Infect Dis Clin North Am 2017 Mar;31(1):81-93
    Division of Infectious Disease, Rhode Island Hospital, The Miriam Hospital, Brown University Alpert School of Medicine, Providence, RI, USA.
    Legionnaire's disease is a nonzoonotic atypical pneumonia caused by Legionella sp that occurs sporadically or in outbreaks. Legionnaire's disease pneumonia is accompanied by several extrapulmonary clinical and laboratory findings. Rather than testing all pneumonias for Legionnaire's disease, the clinical challenge is to recognize the diagnostic significance of Legionnaire's disease's. Read More

    Hypokalaemia in Sjögren's syndrome: the missing piece.
    Clin Med (Lond) 2017 Feb;17(1):40-42
    National University Health System, Singapore and Yong Loo Lin School of Medicine, National University Singapore, Singapore.
    A 58-year-old Chinese woman with well controlled type 1 diabetes mellitus presented with acute and progressive bilateral lower limb weakness. Investigations revealed severe hypokalaemia (1.3 mmol/L) and hypophosphataemia (<0. Read More

    The Mechanism of Valproic Acid-Induced Fanconi Syndrome Involves Mitochondrial Dysfunction and Oxidative Stress in Rat Kidney.
    Nephrology (Carlton) 2017 Jan 31. Epub 2017 Jan 31.
    Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
    Aim: Drug-induced kidney proximal tubular injury and renal failure (Fanconi syndrome; FS) is a clinical complication. Valproic acid (VPA) is among the FS-inducing drugs. The current investigation was designed to evaluate the role of mitochondrial dysfunction and oxidative stress in VPA-induced renal injury. Read More

    Fibroblast Growth Factor 23-Mediated Bone Disease.
    Endocrinol Metab Clin North Am 2017 Mar 14;46(1):19-39. Epub 2016 Dec 14.
    Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
    Fibroblast growth factor 23 (FGF23) is an important regulator of phosphate and vitamin D metabolism and its excessive or insufficient production leads to a wide variety of skeletal disorders. This article reviews the FGF23-α-Klotho signaling pathway, highlighting the latest developments in FGF23 regulation and action, and describes the disorders associated with FGF23 excess or deficiency. Read More

    X-linked hypophosphatemia and growth.
    Rev Endocr Metab Disord 2017 Jan 27. Epub 2017 Jan 27.
    Division of Pediatrics, Department of Medicine. Faculty of Medicine, University of Oviedo, Oviedo, Asturias, Spain.
    X-Linked hypophosphatemia (XLH) is the most common form of hereditary rickets caused by loss-of function mutations in the PHEX gene. XLH is characterized by hypophosphatemia secondary to renal phosphate wasting, inappropriately low concentrations of 1,25 dihydroxyvitamin D and high circulating levels of fibroblast growth factor 23 (FGF23). Short stature and rachitic osseous lesions are characteristic phenotypic findings of XLH although the severity of these manifestations is highly variable among patients. Read More

    Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases.
    Oncol Lett 2017 Jan 17;13(1):307-314. Epub 2016 Nov 17.
    Department of Gastroenterology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
    The aim of the present study was to identify monitoring and prevention measures as well as predictive factors for early detection of renal toxicity associated with long-term administration of adefovir dipivoxil in order to avoid progression to Fanconi syndrome. Clinical data of 28 patients with Fanconi syndrome caused by long-term administration of adefovir dipivoxil for the treatment of chronic hepatitis B virus (HBV) infection were collected pre-and post-administration for analysis. Patients presented with fatigue, progressive systemic pain in multiple bones and joints, as well as difficulty in walking and pathological fractures in a number of severe cases. Read More

    Musculoskeletal oncogenic osteomalacia-An experience from a single centre in South India.
    J Orthop 2017 Mar 6;14(1):184-188. Epub 2017 Jan 6.
    Department of Endocrinology, Christian Medical College, Vellore, India.
    Background: Oncogenic osteomalacia is an acquired form of hypophosphatemic osteomalacia where the tumour resection may lead to cure of the disease. Tumours originating from the musculoskeletal region form an important subgroup of oncogenic osteomalacia.

    Methods: This was a retrospective study conducted at a tertiary care centre in south India where we analyzed the hospital records of all the patients with musculoskeletal oncogenic osteomalacia from January 2010-April 2016. Read More

    Successful treatment of tumour-induced osteomalacia after resection of an oral peripheral ossifying fibroma.
    BMJ Case Rep 2017 Jan 24;2017. Epub 2017 Jan 24.
    Department of Radiology, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
    Tumour-induced osteomalacia is a paraneoplastic syndrome wherein bone is affected by a hormone from a tumour that causes renal phosphate wasting and hypophosphataemia. Here, we present the case of a 31-year-old man who has been suffering from generalised bone pains and a spine deformity that led to loss of height. Pertinent findings are low serum phosphorus, low vitamin D and decreased bone mineral density. Read More

    The Rare Bone Disease Working Group: report from the 2016 American Society for Bone and Mineral Research Annual Meeting.
    Bone 2017 Jan 20. Epub 2017 Jan 20.
    Division of Endocrinology and Metabolism and the Institute for Human Genetics, Department of Medicine, University of California, San Francisco, CA, United States.
    A working group on rare bone diseases was held in Atlanta, Georgia as part of the 2016 annual meeting of the American Society for Bone and Mineral Research. The meeting was organized by Matthew Drake. Given recent advances in our understanding of fibrodysplasia ossificans progressiva (FOP), the initial portion of the program was devoted to basic, translational, and clinical aspects of FOP. Read More

    Successful Treatment of Suspected Pulmonary Arterial Hypertension in a Mealy Amazon Parrot (Amazona farinose).
    J Avian Med Surg 2016 Dec;30(4):368-373
    A 25-year-old, male mealy Amazon parrot (Amazona farinose) with a history of polycythemia, hepatomegaly, and epistaxis was evaluated for progressive lethargy and anorexia. Clinical laboratory testing revealed severe polycythemia (71%), hypophosphatemia (1.6 mg/dL), and mild hypokalemia (2. Read More

    Revisiting the refeeding syndrome: Results of a systematic review.
    Nutrition 2016 Jun 8. Epub 2016 Jun 8.
    Medical University Department, Clinic for Endocrinology/Metabolism/Clinical Nutrition, Kantonsspital Aarau, Aarau and Medical Faculty of the University of Basel, Switzerland. Electronic address:
    Objective: Although described >70 y ago, the refeeding syndrome (RFS) remains understudied with lack of standardized definition and treatment recommendations. The aim of this systematic review was to gather evidence regarding standardized definition, incidence rate and time course of occurrence, association with adverse clinical outcomes, risk factors, and therapeutic strategies to prevent or treat this condition.

    Methods: We searched MEDLINE and EMBASE for interventional and observational clinical trials focusing on RFS, excluding case reports and reviews. Read More

    Corn-Soy-Blend Fortified with Phosphorus to Prevent Refeeding Hypophosphatemia in Undernourished Piglets.
    PLoS One 2017 12;12(1):e0170043. Epub 2017 Jan 12.
    Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark.
    Background: Phosphorus (P) levels in refeeding diets are very important as undernourished children are at risk of hypophosphatemia during refeeding. For this reason, conventional corn-soy-blends (CSB) have been reformulated by the World Food Programme to obtain a mono-calcium-phosphate fortified product (CSB+) and a product further fortified with skim milk powder (CBS++).

    Methods: Using a piglet model of undernourished children, we hypothesized that feeding of CSB+, CSB++ or CSB+ with added whey permeate (CSB+/wp) would help to prevent refeeding hypophosphatemia. Read More

    Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients.
    Hepatol Res 2017 Jan 12. Epub 2017 Jan 12.
    Department of Gastroenterology, Numazu City Hospital, Numazu, Japan.
    Aim: In chronic hepatitis B patients receiving 10 mg adefovir, dose reduction is recommended when renal injury appears. However, recovery is not always achieved and markers that recommend switching to another antiviral agent are unknown. We investigated adefovir-related renal injury, recovery after dose reduction, and their predictors. Read More

    Life threatening nutritional deficiencies in a dialysis patient.
    Hemodial Int 2017 Jan 11. Epub 2017 Jan 11.
    Division of Nephrology, University of Missouri Health Science Center, Columbia, Missouri, 65212.
    Nutritional deficiencies are very common among the patient on chronic hemodialysis. But they can be easily overlooked or misdiagnosed. Deficiencies of trace elements and phosphorous is rare among this patient population but if neglected can lead to catastrophic effects. Read More

    Raf Kinases Are Essential for Phosphate Induction of ERK1/2 Phosphorylation in Hypertrophic Chondrocytes and Normal Endochondral Bone Development.
    J Biol Chem 2017 Feb 10;292(8):3164-3171. Epub 2017 Jan 10.
    From the Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114,
    Hypophosphatemia causes rickets by impairing hypertrophic chondrocyte apoptosis. Phosphate induction of MEK1/2-ERK1/2 phosphorylation in hypertrophic chondrocytes is required for phosphate-mediated apoptosis and growth plate maturation. MEK1/2 can be activated by numerous molecules including Raf isoforms. Read More

    [Refeeding syndrome in geriatric patients : A frequently overlooked complication].
    Z Gerontol Geriatr 2017 Jan 9. Epub 2017 Jan 9.
    Institut für Biomedizin des Alterns, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nürnberg, Deutschland.
    The refeeding syndrome is a life-threatening complication that can occur after initiation of a nutrition therapy in malnourished patients. If the risk factors and pathophysiology are known, the refeeding syndrome can effectively be prevented and treated, if recognized early. A slow increase of food intake and the close monitoring of serum electrolyte levels play an important role. Read More

    Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    BMC Cancer 2017 Jan 6;17(1):27. Epub 2017 Jan 6.
    Department of Medical Oncology (Centre d'Essais Clinique Précoces en Cancérologie [CEPEC]), Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France.
    Background: Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy.

    Methods: From 2007 to 2011, metabolic toxicities were retrospectively collected in patients treated with an mTORi (everolimus, temsirolimus) for a metastatic renal cell carcinoma (mRCC) in a single institution. Read More

    Outcomes of an inpatient refeeding protocol in youth with anorexia nervosa: Rady Children's Hospital San Diego/University of California, San Diego.
    J Eat Disord 2017 3;5. Epub 2017 Jan 3.
    Division of Academic General Pediatrics and Community Health, Department of Pediatrics, University of California, San Diego School of Medicine and Rady Children's Hospital of San Diego, 7910 Frost Street, Suite 300, San Diego, CA 92123 USA ; 9500 Gilman Drive, MC 0874, La Jolla, CA 92093 USA.
    Background: Current guidelines for nutritional rehabilitation in hospitalized restrictive eating disorder patients recommend a cautious approach to refeeding. Several studies suggest that higher calorie diets may be safe and effective, but have traditionally excluded severely malnourished patients. The goal of this study was to evaluate the safety of a higher calorie nutritional rehabilitation protocol (NRP) in a broad sample of inpatients with restrictive eating disorders, including those who were severely malnourished. Read More

    Risk factors for death in children during inpatient treatment of severe acute malnutrition: a prospective cohort study.
    Am J Clin Nutr 2017 Feb 28;105(2):494-502. Epub 2016 Dec 28.
    Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
    Background: Children who receive in-hospital treatment of severe acute malnutrition often have high mortality rates, and the reasons are not well understood.

    Objective: We assessed risk factors for death in children who were treated for malnutrition in a hospital.

    Design: In a prospective observational study of 120 children who were receiving in-hospital treatment of severe acute malnutrition in Uganda with therapeutic formulas F-75 and F-100, we collected data on symptoms, clinical findings, plasma markers of refeeding syndrome (electrolytes and phosphate), and acute phase reactants, and recorded the nutritional therapy given in hospital. Read More

    Hypertension is a characteristic complication of X-linked hypophosphatemia.
    Endocr J 2016 Dec 27. Epub 2016 Dec 27.
    Division of Genetic Research, Tokyo Metropolitan Children's Medical Center, Tokyo 183-8561, Japan.
    X-linked hypophosphatemia (XLH) is a group of rare disorders caused by defective proximal tubular reabsorption of phosphate. Mutations in the PHEX gene are responsible for the majority of cases. There are very few reports of long-term complications of XLH other than skeletal and dental diseases. Read More

    Outcomes of an inpatient refeeding protocol in youth with Anorexia Nervosa and atypical Anorexia Nervosa at Children's Hospitals and Clinics of Minnesota.
    J Eat Disord 2016 19;4:35. Epub 2016 Dec 19.
    University of California, San Francisco Department of Psychiatry, San Francisco, California USA.
    Background: Historically, inpatient protocols have adopted relatively conservative approaches to refeeding in Anorexia Nervosa (AN) in order to reduce the risk of refeeding syndrome, a potentially fatal constellation of symptoms. However, increasing evidence suggests that patients with AN can tolerate higher caloric prescriptions during treatment, which may result in prevention of initial weight loss, shorter hospital stays, and less exposure to the effects of severe malnutrition. Therefore the present study sought to examine the effectiveness of a more accelerated refeeding protocol in an inpatient AN and atypical AN sample. Read More

    A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
    Endocrinology 2016 Dec 22:en20161642. Epub 2016 Dec 22.
    1 Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Mutations in the dentin matrix protein 1 (DMP1) gene cause autosomal recessive hypophosphatemic rickets (ARHR). Hypophosphatemia in ARHR results from increased circulating levels of a phosphaturic hormone, fibroblast growth factor 23 (FGF23). Similarly, elevated FGF23, caused by mutations in the PHEX gene, is responsible for the hypophosphatemia in X-linked hypophosphatemic rickets (XLH). Read More

    A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
    Invest New Drugs 2016 Dec 21. Epub 2016 Dec 21.
    University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI, 53792, USA.
    Background A wide variety of human cancers exhibit dysregulated c-Met activity that has implications in oncogenesis. Phosphorylation of c-Met results in activation of the PI3K/AKT/mTOR pathway. Combined blockade of c-Met and mTOR pathways has shown efficacy in preclinical studies. Read More

    Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum.
    Cardiorenal Med 2016 Nov 30;7(1):60-65. Epub 2016 Sep 30.
    Diabetes and Cardiovascular Center, Department of Medicine, University of Missouri, Columbia, Mo., USA; Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Mo., USA; Harry S. Truman VA Hospital, Columbia, Mo., USA.
    Phosphorus is a key component of bone, and a deficiency results in poor mineralization along with other systemic symptoms of hypophosphatemia. Various causes of hypophosphatemia with renal wasting of phosphorus have been identified. These include the Fanconi syndrome, various genetic mutations of fibroblast growth factor 23 (FGF23) handling and the sodium/phosphate cotransporter, and those due to FGF23 secretion by mesenchymal tumors. Read More

    A Quick Reference on Phosphorus.
    Vet Clin North Am Small Anim Pract 2017 Mar 14;47(2):257-262. Epub 2016 Dec 14.
    Small Animal Clinical Sciences, University of Florida, 2015 Southwest 16th Avenue, Gainesville, FL 32608, USA. Electronic address:
    Phosphorus, or phosphate, is the body's major intracellular anion involved in numerous biological processes. Most phosphate is intracellular, with the remaining amount contained within soft tissues and the extracellular space. Parathyroid hormone, calcitriol, calcitonin, and phosphatonins regulate normal phosphate homeostasis by adjusting renal and/or gastrointestinal absorption and/or excretion. Read More

    Inhibition of cancer cell mitosis by reducing the availability of phosphate.
    Med Hypotheses 2016 Nov 24;96:66-67. Epub 2016 Sep 24.
    Greenwich District Hospital, London, United Kingdom. Electronic address:
    The addition of phosphate groups is an essential requirement for the proper functioning of cyclin and cyclin dependent kinase which control various stages in the mitotic division of cancer cells. Thus limiting the availability of phosphate is likely to interfere with the metabolism of rapidly growing malignant cells. The human hormone glucagon and the anti metabolite mithramycin reduce serum phosphate by increasing phosphaturia and are both very effective in treating Paget's disease of bone, a precancerous condition. Read More

    Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
    Target Oncol 2016 Dec 9. Epub 2016 Dec 9.
    Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.
    Background: Angiogenesis has been a major target of novel drug development in hepatocellular carcinoma (HCC). It is hypothesized that the combination of two antiangiogenic agents, sorafenib and bevacizumab, will provide greater blockade of angiogenesis.

    Objective: To determine the optimal dose, safety, and effectiveness of dual anti-angiogenic therapy with sorafenib and bevacizumab in patients with advanced HCC. Read More

    Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c.
    Bone 2016 Dec 7;97:15-19. Epub 2016 Dec 7.
    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Electronic address:
    Objective: To identify a genetic basis for markedly reduced bone density and multiple fractures in an adult patient with hypophosphatemia and hypercalciuria.

    Subjects: A 54-year-old Vietnamese man, his unaffected two daughters and wife.

    Methods: We performed biochemical studies and sequenced the SLC34A3 gene using genomic DNA from peripheral blood mononuclear cells. Read More

    FGF23 is not required to regulate fetal phosphorus metabolism but exerts effects within 12 hours after birth.
    Endocrinology 2016 Dec 8:en20161369. Epub 2016 Dec 8.
    1 Faculty of Medicine - Endocrinology, Memorial University of Newfoundland, St. John's, NL, Canada.
    Loss of fibroblast growth factor 23 (FGF23) causes hyperphosphatemia, extraskeletal calcifications, and early mortality; excess FGF23 causes hypophosphatemia with rickets or osteomalacia. However, FGF23 may not be important during fetal development. FGF23 deficiency (Fgf23 null) and FGF23 excess (Phex null) did not alter fetal phosphorus or skeletal parameters. Read More

    The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
    Int Immunopharmacol 2017 Jan 1;42:168-175. Epub 2016 Dec 1.
    Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, China. Electronic address:
    Background: The purpose of this study was to assess the efficacy and safety between tenofovir and entecavir in the treatment of CHB and HBV related cirrhosis through Meta-analysis. Methods The electronic databases of PubMed, the Cochrane Library, Nature, CNKI and WanFang data were searched. The key words were: ("tenofovir", "entecavir") and ("Chronic Hepatitis B" or "CHB") and "Liver cirrhosis". Read More

    Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    PLoS One 2016 1;11(12):e0167146. Epub 2016 Dec 1.
    Medical University of Innsbruck, Department of Medicine II, Gastroenterology and Hepatology, Anichstr. Innsbruck, Austria.
    Background: Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM.

    Aim: To characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort. Read More

    Fanconi Syndrome Associated with Hyponatremia in Two Patients with Legionella Pneumonia.
    Intern Med 2016;55(23):3479-3484. Epub 2016 Dec 1.
    Department of Nephrology, Toyohashi Municipal Hospital, Japan.
    Legionella pneumophila is a cause of community-acquired pneumonia that is reported to induce electrolyte disorders, including hyponatremia, hypokalemia, and hypophosphatemia. We herein report two Japanese men with Legionella pneumonia and hyponatremia and hypophosphatemia. These findings were associated with an elevation of urinary low-molecular-weight tubular protein, including urinary β2-microglobulin, N-acetyl-β-D-glucosaminidase, the fractional excretion of phosphate and uric acid, and the presence of glycosuria and panaminoaciduria, suggesting that their electrolyte disorders had been caused by Fanconi syndrome. Read More

    Mosaic NRAS Q61R mutation in a child with giant congenital melanocytic naevus, epidermal naevus syndrome and hypophosphataemic rickets.
    Clin Exp Dermatol 2017 Jan 30;42(1):75-79. Epub 2016 Nov 30.
    Department of Paediatric Dermatology, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK.
    The association of hypophosphataemic rickets with verrucous epidermal naevus (EN) and elevated fibroblast growth factor 23 levels is known as cutaneous-skeletal hypophosphataemia syndrome (CSHS), and can be caused by somatic activating mutations in RAS genes. We report a unique patient with CSHS associated with giant congenital melanocytic naevus (CMN), neurocutaneous melanosis and EN syndrome, manifesting as facial linear sebaceous naevus, developmental delay and ocular dermoids. An activating mutation Q61R in the NRAS gene was found in affected skin and ocular tissue but not blood, implying that the disparate manifestations are due to a multilineage activating mutation (mosaic RASopathy). Read More

    Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia.
    Orphanet J Rare Dis 2016 Nov 28;11(1):160. Epub 2016 Nov 28.
    Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Unit, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
    Background: Health-related quality of life of adults with osteogenesis imperfecta (OI), fibrous dysplasia (FD) and X-linked hypophosphatemia (XLH) remains poorly described. The aim of this study was to describe the HRQoL of adults with osteogenesis imperfecta, fibrous dysplasia and X-linked hypophophataemia and perform a cost-utility simulation to calculate the maximum cost that a health care system would be willing to pay for a hypothetical treatment of a rare bone disease.

    Results: Participants completed the EQ-5D-5 L questionnaire between September 2014 and March 2016. Read More

    1 OF 108